Nuveen LLC Buys New Stake in Omnicell, Inc. $OMCL

Key Points

• Nuveen LLC acquired 177,848 shares of Omnicell, Inc., valued at approximately $6.2 million, representing about 0.38% of the company's shares as of its latest SEC filing.
• Omnicell's stock is currently priced at $33.09 with a market capitalization of $1.52 billion, while the stock price has seen a one-year range of $22.66 to $55.74.
• A number of analysts have raised their target prices for Omnicell, with Wells Fargo increasing its target from $37 to $40, rating the stock as "overweight."

Nuveen LLC acquired a new stake in Omnicell, Inc. (NASDAQ:OMCL - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 177,848 shares of the company's stock, valued at approximately $6,218,000. Nuveen LLC owned about 0.38% of Omnicell at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of OMCL. Victory Capital Management Inc. lifted its position in Omnicell by 10.1% during the 1st quarter. Victory Capital Management Inc. now owns 1,680,347 shares of the company's stock worth $58,745,000 after acquiring an additional 154,038 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in Omnicell by 31.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,642,626 shares of the company's stock worth $73,127,000 after acquiring an additional 394,820 shares during the last quarter. Lazard Asset Management LLC lifted its position in Omnicell by 81.6% during the 4th quarter. Lazard Asset Management LLC now owns 1,641,817 shares of the company's stock worth $73,093,000 after acquiring an additional 737,536 shares during the last quarter. ArrowMark Colorado Holdings LLC lifted its position in Omnicell by 4.9% during the 4th quarter. ArrowMark Colorado Holdings LLC now owns 1,196,990 shares of the company's stock worth $53,290,000 after acquiring an additional 56,117 shares during the last quarter. Finally, Toronto Dominion Bank acquired a new position in Omnicell during the 4th quarter worth $30,637,000. Institutional investors and hedge funds own 97.70% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Benchmark cut their target price on shares of Omnicell from $62.00 to $40.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Piper Sandler cut their target price on shares of Omnicell from $57.00 to $55.00 and set an "overweight" rating for the company in a research report on Monday, August 11th. Bank of America boosted their target price on shares of Omnicell from $30.00 to $34.00 and gave the stock a "neutral" rating in a research report on Friday, May 23rd. Wall Street Zen lowered shares of Omnicell from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 9th. Finally, Wells Fargo & Company upped their price objective on shares of Omnicell from $37.00 to $40.00 and gave the company an "overweight" rating in a research report on Monday, July 21st. Four research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat, Omnicell presently has a consensus rating of "Moderate Buy" and a consensus target price of $46.71.

Omnicell Stock Performance

Shares of OMCL traded down $0.69 during trading hours on Friday, reaching $32.59. 595,171 shares of the company traded hands, compared to its average volume of 569,766. The stock's fifty day moving average is $30.07 and its 200 day moving average is $31.50. The stock has a market cap of $1.50 billion, a P/E ratio of 65.18, a price-to-earnings-growth ratio of 7.12 and a beta of 0.82. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.24 and a current ratio of 1.42. Omnicell, Inc. has a 1-year low of $22.66 and a 1-year high of $55.74.

Omnicell (NASDAQ:OMCL - Get Free Report) last posted its earnings results on Thursday, July 31st. The company reported $0.45 earnings per share for the quarter, beating analysts' consensus estimates of $0.30 by $0.15. The business had revenue of $290.56 million for the quarter, compared to analysts' expectations of $275.57 million. Omnicell had a net margin of 2.01% and a return on equity of 4.27%. The firm's revenue for the quarter was up 5.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.51 earnings per share. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. Equities research analysts anticipate that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.